News > Latest News

Walk News | Sponsor & Foundation News | News in the Parkinson's Disease Community

Sponsor & Foundation News

Parkinson's Foundation Designates Three Centers of Excellence in Parkinson's Care

Sunovion Presents Data from Pivotal Phase 3 Study of Apomorphine Sublingual Film (APL-130277)

Adamas Presents New Data Analysis Demonstrating that GOCOVRI™ Reduces Transitions between Dyskinesia and OFF Episodes Throughout the Day

Medtronic Launches New Clinician Programmer for Deep Brain Stimulation Therapy

Sunovion Announces FDA Acceptance of New Drug Application for Apomorphine Sublingual Film (APL-130277)

Acorda Announces EMA Validation of the MAA Submission for INBRIJA™

Introducing Little Big Things™ from Sunovion Pharmaceuticals Inc.

Adamas Announces Multiple Data Presentations at the American Academy of Neurology Annual Meeting

Sunovion Submits New Drug Application to the FDA for Apomorphine Sublingual Film for the Treatment of OFF Episodes Associated with PD

Adamas Announces Publication of Data Supporting the Benefits of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia

Lundbeck to acquire Prexton Therapeutics

Acorda Launches New Initiative - “Live Well. Do Tell.™” to Support People with Parkinson’s

Nuplazid and Clozaril Are Most Reliable Parkinson’s Psychosis Therapies, Review Finds

Acorda Announces FDA Acceptance of New Drug Application for INBRIJA™

Adamas Announces Publication of Amantadine Immediate Release Subgroup Analysis from EASE LID 2 Open-label Study

Sunovion Announces Positive Results from Study of Apomorphine Sublingual Film in Patients with PD

Adamas Announces U.S. Commercial Launch of GOCOVRI™ the First and Only FDA Approved Medication for the Treatment of Dyskinesia in Parkinson's Disease Patients

Boston Scientific Receives U.S. FDA Approval for the Vercise™ Deep Brain Stimulation System

Acorda Resubmits NDA for Parkinson's Disease Candidate Inbrija

Acorda Resubmits New Drug Application for INBRIJA™ (CVT-301, levodopa inhalation powder)

Voyager Therapeutics Highlights Lead Program VY-AADC for Advanced PD

Voyager’s AADC Gene Therapy Shows Promise as Maintenance Therapy for Parkinson’s Disease

GOCOVRI for Dyskinesia Gets Orphan Drug Designation

Distinguished Movement Disorders Researchers to Lead Fresco Institute at NYU Langone Health

New Phase 3 Trial to Test Nuplazid for Parkinson’s Psychosis in Array of Dementia Patients

Voyager Therapeutics Presents Promising Parkinson’s Data

Adamas Announces FDA Approval of GOCOVRI™ as First and Only Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients

back to top